Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Therapeutics: turnover.

McCarthy N.

Nat Rev Cancer. 2013 Jun;13(6):380-1. doi: 10.1038/nrc3528. Epub 2013 Apr 25. No abstract available.

PMID:
23615693
2.

Doxorubicin enhances nucleosome turnover around promoters.

Yang F, Kemp CJ, Henikoff S.

Curr Biol. 2013 May 6;23(9):782-7. doi: 10.1016/j.cub.2013.03.043. Epub 2013 Apr 18.

3.

Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.

Bridewell DJ, Finlay GJ, Baguley BC.

Oncol Res. 1997;9(10):535-42.

PMID:
9507531
4.

Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.

Temma K, Akera T, Chugun A, Kondo H, Hagane K, Hirano S.

Eur J Pharmacol. 1993 Apr 6;234(2-3):173-81.

PMID:
8482324
5.

Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.

Lehne G, De Angelis P, Clausen OP, Rugstad HE.

Int J Clin Pharmacol Ther. 1998 Feb;36(2):89-92. No abstract available.

PMID:
9520154
6.

Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

Skovsgaard T.

Eur J Haematol Suppl. 1987;47:7-20. Review. No abstract available.

PMID:
3552720
7.

[Studies on collagenase inhibitors. III. Inhibitory effects of anthracyclines on bacterial collagenase].

Tanaka T, Metori K, Mineo S, Matsumoto H, Satoh T.

Yakugaku Zasshi. 1991 Jan;111(1):70-2. Japanese.

PMID:
1647453
8.

Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells.

Aries A, Trentesaux C, Ottolenghi S, Jardillier JC, Jeannesson P, Doubeikovski A.

Blood. 1996 Apr 1;87(7):2885-90.

9.

Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.

Ando S, Sasada M, Uchino H, Kagawa D, Ueda T, Nakamura T.

Nihon Gan Chiryo Gakkai Shi. 1986 Dec 20;21(10):2343-55. No abstract available.

PMID:
3471823
10.

Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.

Kiguchi T, Niiya K, Shibakura M, Miyazono T, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Nakata Y, Harada M.

Int J Cancer. 2001 Sep;93(6):792-7.

11.

Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.

Dartsch DC, Schaefer A, Boldt S, Kolch W, Marquardt H.

Apoptosis. 2002 Dec;7(6):537-48.

PMID:
12370496
12.

The effect of vivo doxorubicin (adriamycin) and aclacinomycin administration on guanylate cyclase activity in rat tissue.

Lehotay DC, Levey BA, Rogerson BJ, Levey GS.

Proc Soc Exp Biol Med. 1981 Sep;167(4):459-62. No abstract available.

PMID:
6116236
13.
14.

Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.

Levey BA, Ruiz E, Rogerson B, Lehotay DC, Levey GS.

Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1127-8. No abstract available.

PMID:
6109566
15.

Inhibition of nitric oxide synthase by antineoplastic anthracyclines.

Luo D, Vincent SR.

Biochem Pharmacol. 1994 Jun 1;47(11):2111-2.

PMID:
7516659
16.
17.

An artificially constructed radiation-responsive promoter is activated by doxorubicin.

Ogawa R, Morii A, Watanabe A, Cui ZG, Kagiya G, Doi N, Zhao QL, Feril LB Jr.

Cancer Gene Ther. 2012 May;19(5):345-51. doi: 10.1038/cgt.2012.7. Epub 2012 Mar 9.

PMID:
22402623
18.

Mechanisms in inhibitory action of aclarubicin on contractility of rat aorta.

Wakabayashi I, Hatake K, Masui H, Sakamoto K.

J Pharm Pharmacol. 1995 Dec;47(12A):1025-8.

PMID:
8932688
19.

[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome].

Shibuya T, Nagafuji H, Mizuno S, Harada M.

Rinsho Ketsueki. 1996 Sep;37(9):782-4. Japanese. No abstract available.

PMID:
8914462
20.

Conserved cytostatic activity of aclarubicin in a doxorubicin selected Friend leukaemia cell line with multifactorial multidrug resistance.

Erttmann R, Münchmeyer M, Looft G, Winkler K.

Eur J Cancer. 1991;27(8):1064. No abstract available.

PMID:
1832898

Supplemental Content

Support Center